ha ha ha ...what a joke. If primary end points are met then why another phase-3 needed? and what if next phase-3 fails? do they have money to do another phase-3? lots of pumper around here in this message board, be careful. this will go back to $1.20 next week.
ha ha ha !!... better load TTHI... earning today after hr, most like an update of their Alz drug candidate's phase-3 discussion with FDA.
AVXL is a epic failure... load TTHI... phase-2 works in s subgroup, phase-3 anytime.. TTHI could be the next AXON
TTHI breaking out... their Phase-2 showed efficacy for a certain subgroup and Phase-3 kick off discussion with FDA underway ..AVXL is a epic failure, load TTHI ..next AXON
TTHI could give best ROI in short term.. TTHI's AD drug candidate ELND005 shows positive efficacy in severe agitation and aggression in AD patients and completed Phase -2, Phase-3 kick off any time.
Plans for Further ELND005 Clinical Development
Over the next few months, TTIL intends to submit a request to the FDA to discuss the data from the completed Phase 2/3 study. The objective of the meeting will be to seek guidance on the design of Phase 3 clinical studies for the ELND005 program in severe agitation and aggression in AD patients. Since AD patients with severe agitation and aggression are in the most need for treatment and most likely candidates for institutionalization, ELND005 could provide significant benefit and impact to this patient population and their caregivers, as well as reduce overall costs in managing this patient population. In parallel, TTIL has prepared sufficient drug supply for future phase 3 studies and begun to identify potential clinical sites for enrollment.
TTHI has fast track designation as well:
ELND005 has received fast track designation from the psychiatry division of the United States Food and Drug Administration for its potential as a treatment of Neuropsychiatric Symptoms (including Agitation and Aggression) in AD. There are no FDA approved medications for severe agitation and aggression in Alzheimer's disease.
TTHI taking off.... phase-3 kick off anytime for its lead AD drug candidate. only 38M shares and no dilution $30M cash on hand.
True. AD is most complex disease at this time. Huge space to play with. TTHI's phase 2 showing strong result for selected sub-group and they are in progress in discussion with FDA to plan for Phase-3. I believe that puts TTHI ahead of AVXL.
Sentiment: Strong Buy
TTHI in progress to discuss with FDA to plan for phase-3 for its AD drug. TTHI = huge potential. AVXL could dilute any time , not enough cash and it's trading with too much hype. TTHI much better play.
My horoscope says big money on Friday from stock. Let's see. This stock could erupt anytime like a volcano.
Sentiment: Strong Buy
Watch this BioTech : 22nd Century Group, Inc. (XXII) ... pioneer in zero nicotine tobacco. gigantic potential.
Mars is dead 4 billions years ago,.. and lots of people still pumping Mars hype and needless to say eElune is the biggest pumper. Why? May be attract more investors in Spase-Exx?